Clinical Trials Directory

Trials / Completed

CompletedNCT01465672

Copeptin as a Diagnostic Marker in the Management of Neurosurgical Patients With Disturbance of Water Homeostasis

Status
Completed
Phase
Study type
Observational
Enrollment
125 (actual)
Sponsor
University Hospital, Basel, Switzerland · Academic / Other
Sex
All
Age
15 Years
Healthy volunteers
Not accepted

Summary

Water imbalance and consecutive electrolyte disturbances are common in the postoperative course of neurosurgical patients after pituitary surgery. Diabetes insipidus (DI) may complicate the postoperative course in as many as 30% of patients. Early and accurate diagnosis of water and electrolyte disturbances postoperatively is important for an adequate fluid and drug administration. However, identifying the causes is challenging/ ambiguous in clinical practice. Levels of antidiuretic hormone (ADH) might contribute to a straightforward diagnosis, though, its measurement is cumbersome. ADH is derived from a larger precursor peptide along with copeptin, which is a more stable peptide directly mirroring the production of ADH. Copeptin can be assayed readily in plasma. Aim: To investigate whether copeptin can accurately diagnose postoperative disturbances of water homeostasis (i.e. Diabetes insipidus and SIADH) in a cohort of patients undergoing intracranial tumor surgery.

Conditions

Timeline

Start date
2011-10-01
Primary completion
2013-12-01
Completion
2013-12-01
First posted
2011-11-07
Last updated
2014-05-20

Locations

2 sites across 1 country: Switzerland

Source: ClinicalTrials.gov record NCT01465672. Inclusion in this directory is not an endorsement.

Copeptin as a Diagnostic Marker in the Management of Neurosurgical Patients With Disturbance of Water Homeostasis (NCT01465672) · Clinical Trials Directory